News
GOSS
1.120
+2.75%
0.030
Weekly Report: what happened at GOSS last week (0715-0719)?
Weekly Report · 4d ago
Gossamer Bio (GOSS) Receives a Buy from Piper Sandler
TipRanks · 07/15 10:48
Weekly Report: what happened at GOSS last week (0708-0712)?
Weekly Report · 07/15 09:23
Weekly Report: what happened at GOSS last week (0701-0705)?
Weekly Report · 07/08 09:23
Weekly Report: what happened at GOSS last week (0624-0628)?
Weekly Report · 07/01 09:23
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
Oppenheimer initiated coverage on Gossamer Bio Inc with an Outperform rating and a price target of $9. The company is focused on developing and commercializing seralutinib for pulmonary arterial hypertension. It stands out with its clean long-term safety profile, Oppenheimer says.
Benzinga · 06/25 18:39
Tuesday 6/25 Insider Buying Report: GOSS, EXFY
NASDAQ · 06/25 18:08
Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern about the company's prospects. The Dow Jones index closed higher by over 250 points on Monday. Recent notable insider transactions for penny stocks include Pacific Health Care Organization, Inc. And Gossamer Bio. System1 and System1, Inc are among the companies with penny stocks with recent insider transactions.
Benzinga · 06/25 12:51
GOSSAMER BIO INC <GOSS.O>: OPPENHEIMER INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $9
Reuters · 06/25 12:20
Gossamer Bio Initiated at Outperform by Oppenheimer
Dow Jones · 06/25 09:51
Gossamer Bio Price Target Announced at $9.00/Share by Oppenheimer
Dow Jones · 06/25 09:51
Oppenheimer Initiates Coverage On Gossamer Bio with Outperform Rating, Announces Price Target of $9
Benzinga · 06/25 09:40
U.S. RESEARCH ROUNDUP-Alimera Sciences, Comtech Telecommunications, Eli Lilly
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Alimera Sciences, Comtech Telecommunications, Eli Lilly among companies with revised targets. Analysts raise their ratings on several companies, including Apple and FMC. Some analysts also raise their target prices on other companies.
Reuters · 06/25 07:19
Gossamer Bio a new outperform at Oppenheimer on seralutinib for PAH
Oppenheimer initiates Gossamer Bio at outperform on seralutinib for pulmonary arterial hypertension. The firm has a $9 price target for the drug with a 984% upside based on June 24 close. The drug is a inhaled tyrosine kinase inhibitor for PAH.
Seeking Alpha · 06/24 21:57
Weekly Report: what happened at GOSS last week (0617-0621)?
Weekly Report · 06/24 09:24
Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Kaival Brands Innovations Group, Inc. Shares dipped 47% to $1.52 on Friday. The company announced pricing of $6.0 million public offering. American Rebel Holdings, Inc., shares jumped 161% in today's mid-day session. Other stocks moving in the market included Spectaire Holdings, Sarepta Therapeutics and Clover Health Investments.
Benzinga · 06/21 18:04
Gossamer Bio Is Maintained at Buy by Goldman Sachs
Dow Jones · 06/17 16:55
Gossamer Bio Price Target Maintained With a $8.00/Share by Goldman Sachs
Dow Jones · 06/17 16:55
Goldman Sachs Maintains Buy on Gossamer Bio, Maintains $8 Price Target
Benzinga · 06/17 16:45
BUZZ-Gossamer Bio gains after rival Aerovate scraps late-stage trial of lead drug
Gossamer Bio gains after rival Aerovate scraps late-stage trial of lead drug. Shares of drug developer rise 14% to 59 cents after competitor's drug failed on key goals. Gossamer's lead drug, AV-101, tested in adults with pulmonary arterial hypertension.
Reuters · 06/17 15:51
More
Webull provides a variety of real-time GOSS stock news. You can receive the latest news about Gossamer Bio through multiple platforms. This information may help you make smarter investment decisions.
About GOSS
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).